{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:13:40Z","timestamp":1792696420506,"version":"4.5.0"},"reference-count":71,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Osteogenesis Imperfecta (OI) is a group of connective tissue disorders with a broad range of phenotypes characterized primarily by bone fragility. The prevalence of OI ranges from about 1:15,000 to 1:20,000 births. Five types of the disease are commonly distinguished, ranging from a mild (type I) to a lethal one (type II). Types III and IV are severe forms allowing survival after the neonatal period, while type V is characterized by a mild to moderate phenotype with calcification of interosseous membranes. In most cases, there is a reduction in the production of normal type I collagen (col I) or the synthesis of abnormal collagen as a result of mutations in col I genes. Moreover, mutations in genes involved in col I synthesis and processing as well as in osteoblast differentiation have been reported. The currently available treatments try to prevent fractures, control symptoms and increase bone mass. Commonly used medications in OI treatment are bisphosphonates, Denosumab, synthetic parathyroid hormone and growth hormone for children therapy. The main disadvantages of these therapies are their relatively weak effectiveness, lack of effects in some patients or cytotoxic side effects. Experimental approaches, particularly those based on stem cell transplantation and genetic engineering, seem to be promising to improve the therapeutic effects of OI.<\/jats:p>","DOI":"10.3390\/biom11101493","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T21:19:32Z","timestamp":1633900772000},"page":"1493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Osteogenesis Imperfecta: Current and Prospective Therapies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-0918","authenticated-orcid":false,"given":"Malwina","family":"Botor","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-4253","authenticated-orcid":false,"given":"Agnieszka","family":"Fus-Kujawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-3478","authenticated-orcid":false,"given":"Marta","family":"Uroczynska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina L.","family":"Stepien","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-989X","authenticated-orcid":false,"given":"Anna","family":"Galicka","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Medical University of Bialystok, Mickiewicza 2A, 15-222 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-6270","authenticated-orcid":false,"given":"Katarzyna","family":"Gawron","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander L.","family":"Sieron","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"ref_2","first-page":"78","article-title":"Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta","volume":"304","author":"Chu","year":"1983","journal-title":"Nat. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ajmg.a.61366","article-title":"Nosology and classification of genetic skeletal disorders: 2019 revision","volume":"179","author":"Mortier","year":"2019","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/jsbi.1996.0066","article-title":"Mineralization of collagen may occur on fibril surfaces: Evidence from conven-tional and high-voltage electron microscopy and three-dimensional imaging","volume":"117","author":"Landis","year":"1996","journal-title":"J. Struct. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/humu.20799","article-title":"CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta","volume":"29","author":"Baldridge","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jmedgenet-2012-101307","article-title":"Osteogenesis imperfecta type V: Marked phenotypic variability despite the presence of the IFITM5c.\u221214C > T mutation in all patients","volume":"50","author":"Rauch","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jbmr.487","article-title":"Mutations in SERPINF1 cause osteogenesis imperfecta type VI","volume":"26","author":"Homan","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/humu.22139","article-title":"Absence of FKBP10in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix","volume":"33","author":"Barnes","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/ajmg.a.37958","article-title":"Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 muta-tions","volume":"170","author":"Pollitt","year":"2016","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","article-title":"Mutations in WNT1 are a cause of osteogenesis imperfecta","volume":"50","author":"Fahiminiya","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in osterix in a patient with recessive osteo-genesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_16","first-page":"1020","article-title":"Bisphosphonates and bone quality","volume":"15","author":"Miki","year":"2005","journal-title":"Clin. Calcium"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2008.07.006","article-title":"Bone remodelling: Its local regulation and the emergence of bone fragility","volume":"22","author":"Martin","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1302\/1863-2548.13.180190","article-title":"Current concepts in osteogenesis imperfecta: Bone structure, biomechanics and medical management","volume":"13","author":"Nijhuis","year":"2019","journal-title":"J. Child. Orthop."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00198-019-05227-9","article-title":"Intravenous bisphosphonate therapy in children with spinal muscular atrophy","volume":"31","author":"Nasomyont","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nmd.2017.01.019","article-title":"Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity","volume":"27","author":"Wasserman","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1359\/jbmr.090711","article-title":"Risedronate reduces intracortical porosity in women with osteoporosis","volume":"25","author":"Borah","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/2278-330X.119895","article-title":"Denosumab: A comprehensive review","volume":"2","author":"Narayanan","year":"2013","journal-title":"South Asian J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apa.14154","article-title":"Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings","volume":"107","author":"Yanling","year":"2018","journal-title":"Acta Paediatr."},{"key":"ref_26","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014A first prospective trial","volume":"16","author":"Franklin","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","article-title":"Osteogenesis imperfecta and therapeutics","volume":"71","author":"Morello","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","article-title":"Treatment algorithm postmenopausal osteoporosis","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: A prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide (rhPTH(1-34)) are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in pa-tients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00003086-199001000-00036","article-title":"Role of transforming growth factor-beta in bone remodeling","volume":"250","author":"Bonewald","year":"1990","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Management of endocrine disease: Osteogenesis imperfecta: An update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jbmr.3473","article-title":"Skeletal response to soluble activin receptor type IIB in mouse models of osteogenesis imperfecta","volume":"33","author":"Jeong","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Morris, J.C., Tan, A.R., Olencki, T.E., Shapiro, G.I., Dezube, B.J., Reiss, M., Hsu, F.J., Berzofsky, J.A., and Lawrence, D.P. (2014). Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced ma-lignant melanoma or renal cell carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090353"},{"key":"ref_43","unstructured":"(2021, August 30). A Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with BPS804 (ASTEROID). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03118570."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and im-proves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bone.2014.09.009","article-title":"Stem cells and bone diseases: New tools, new perspective","volume":"70","author":"Riminucci","year":"2015","journal-title":"Bone"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/scd.2013.0132","article-title":"Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta","volume":"23","author":"Jones","year":"2014","journal-title":"Stem Cells Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and postnatal Transplantation of Fetal mesenchymal stem cells in osteogenesis imperfecta: A two-center experience","volume":"3","author":"Westgren","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4236\/ojgen.2013.31006","article-title":"Cell therapy of a patient with type III osteogenesis imperfecta caused by mutation in COL1A2 gene and unstable collagen type I","volume":"3","author":"Majka","year":"2013","journal-title":"Open J. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/mt.2011.209","article-title":"Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs","volume":"20","author":"Deyle","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ejhg.2013.198","article-title":"Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta","volume":"22","author":"Rousseau","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cpt.542","article-title":"Genome editing techniques and their therapeutic applications","volume":"101","author":"Calos","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.scr.2019.101622","article-title":"Generation of a patient-specific induced pluripotent stem cell line, KSCBi006-A, for osteogenesis imperfecta type I with the COL1A1, c.3162delT mutation","volume":"41","author":"Kim","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9613258","DOI":"10.1155\/2019\/9613258","article-title":"The application of induced pluripotent stem cells in pathogenesis study and gene therapy for vascular disorders: Current progress and future challenges","volume":"2019","author":"Peng","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"768391","DOI":"10.1155\/2014\/768391","article-title":"A comparative view on human somatic cell sources for iPSC generation","volume":"2014","author":"Raab","year":"2014","journal-title":"Stem Cells Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1016\/j.biomaterials.2013.03.072","article-title":"Delivery of reprogramming factors into fibroblasts for generation of non-genetic induced pluripotent stem cells using a cationicbolaamphiphile as a non-viral vector","volume":"34","author":"Khan","year":"2013","journal-title":"Biomaterials"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13287-017-0642-y","article-title":"The combination of stem cells and tissue engineering: An advanced strategy for blood vessels regeneration and vascular disease treatment","volume":"8","author":"Wang","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/biores.2019.0046","article-title":"Induced pluripotent stem cells: Reprogramming platforms and applications in cell Replacement therapy","volume":"9","author":"Ngai","year":"2020","journal-title":"BioRes. Open Access"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Fus-Kujawa, A., Mendrek, B., Trybus, A., Bajdak-Rusinek, K., Stepien, K., and Sieron, A. (2021). Potential of induced pluripotent stem cells for use in gene therapy: History, molecular bases, and medical perspectives. Biomoleculs, 11.","DOI":"10.3390\/biom11050699"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.17352\/sscrt.000011","article-title":"Cell-penetrating peptides as a tool to deliver biologically active recombinant proteins to generate transgene-free induced pluripotent stem cells","volume":"3","author":"Dey","year":"2017","journal-title":"Stud. Stem Cells Res. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/00914037.2020.1716227","article-title":"Functional star polymers as reagents for efficient nucleic acids delivery into HT-1080 cells","volume":"70","author":"Teper","year":"2021","journal-title":"Int. J. Polym. Mater."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature25164","article-title":"Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents","volume":"553","author":"Gao","year":"2018","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2017.11.013","article-title":"Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice","volume":"107","author":"Rauch","year":"2018","journal-title":"Bone"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101449","DOI":"10.1016\/j.scr.2019.101449","article-title":"Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis im-perfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR\/Cas9 editing","volume":"37","author":"Far","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101453","DOI":"10.1016\/j.scr.2019.101453","article-title":"The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G > T iPSC line and an isogenic control iPSC line","volume":"38","author":"Howden","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Jung, H., Rim, Y., Park, N., Nam, Y., and Ju, J. (2021). Restoration of osteogenesis by CRISPR\/Cas9 genome editing of the mutated COL1A1 Gene in osteogenesis imperfecta. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143141"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.bbadis.2018.02.002","article-title":"4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion","volume":"1864","author":"Besio","year":"2018","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"dmm038521","DOI":"10.1242\/dmm.038521","article-title":"Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate","volume":"12","author":"Besio","year":"2019","journal-title":"Dis. Models Mech."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/hmg\/ddx171","article-title":"The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta","volume":"26","author":"Gioia","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2021.03.001","article-title":"Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta","volume":"98","author":"Garibaldi","year":"2021","journal-title":"Matrix Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119628","DOI":"10.1016\/j.lfs.2021.119628","article-title":"Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor","volume":"278","author":"Duangchan","year":"2021","journal-title":"Life Sci."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/10\/1493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:11:16Z","timestamp":1760166676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/10\/1493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,10]]},"references-count":71,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biom11101493"],"URL":"https:\/\/doi.org\/10.3390\/biom11101493","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,10]]}}}